

January 2024 Pharmacy & Therapeutics Committee Decisions

Aspirus' Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to review and make changes to the Aspirus Medicare Formulary (approved drug list). These changes are reviewed based on clinical evidence, safety, and therapeutic guidelines. All changes that are recommended by P&T for Medicare formularies are tentative until Aspirus receives final CMS approval.

Key

PA: Prior Authorization

QL: Quantity Limit

ST: Step Therapy

NEW DRUG REVIEW			
DRUG	INDICATION	FORMULARY COVERAGE	EFFECTIVE DATE
Elevidys (delandistrogene moxeparvc-rokl)	for the treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD gene	Non-Formulary	N/A
Elrexfio (elranatamab-bcmm)	for the treatment of relapsed or refractory multiple myeloma in adults who have received at least four prior lines of therapy including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody.	Non-Formulary	N/A
Izervay (avacincaptad pegol sodium/pf)	for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)	Non-Formulary	N/A
Veopoz (pozelimab-bbfg)	is indicated for the treatment of CD55-deficient protein-losing enteropathy, also known as CHAPLE disease, in adult and pediatric patients \geq 1 year of age.	Non-Formulary	N/A
Veopoz (pozelimab-bbfg)	is indicated for the treatment of CD55-deficient protein-losing enteropathy, also known as CHAPLE disease, in adult and pediatric patients \geq 1 year of age.	Formulary	02/01/2024

January 2024 Pharmacy & Therapeutics Committee Decisions

<p>Akeega (niraparib/abiraterone) PROTECTED CLASS DRUG</p>	<p>treatment of deleterious or suspected deleterious BRreast CAnCer (BRCA)-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC) in adults with prednisone</p>	<p>Formulary</p>	<p>02/01/2024</p>
<p>Beyfortus (nirsevimab-alip)</p>	<p>for the prevention of RSV lower respiratory tract disease (LRTD) in: 1) Neonates and infants born during or entering their first RSV season; and 2) Children ≤ 24 months of age who remain vulnerable to severe RSV disease through their second RSV season</p>	<p>Formulary</p>	<p>02/01/2024</p>
<p>Bimzelx (bimekizumab-bkzx)</p>	<p>treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy</p>	<p>Non-Formulary</p>	<p>N/A</p>
<p>Lodoco (colchicine)</p>	<p>to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular (CV) death in adults with established atherosclerotic disease or with multiple risk factors for CV disease</p>	<p>Non-Formulary</p>	<p>N/A</p>
<p>Ngenla (somatrogon-ghla)</p>	<p>treatment of pediatric patients aged 3 years and older who have growth failure due to inadequate secretion of endogenous growth hormone</p>	<p>Non-Formulary</p>	<p>N/A</p>
<p>Sohonos capsule (palovarotene)</p>	<p>the reduction in volume of new heterotopic ossification caused by fibrodysplasia ossificans progressiva in adults and pediatric patients aged eight years and older for females and 10 years and older for males. Sohonos received Orphan Drug and Breakthrough Therapy designations from the FDA and was granted Priority Review</p>	<p>Non-Formulary</p>	<p>N/A</p>

January 2024 Pharmacy & Therapeutics Committee Decisions

Daxxify (daxibotulinumtoxinalanm)	Daxxify is indicated for the treatment of cervical dystonia in adults. Daxxify was first approved for cosmetic use by the FDA in 2022 for temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults.	Non-Formulary	N/A
Jesduvroq (daprodustat)	Jesduvroq is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least 4 months.	Non-Formulary	N/A
Talvey (talquetamab-tgvs)	Talvey is indicated for treatment of relapsed or refractory multiple myeloma in adults who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody.	Formulary	02/01/2024
Vanflyta (quizartinib dihydrochloride)	Vanflyta, a kinase inhibitor, is indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of newly diagnosed acute myeloid leukemia (AML) that is FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD)-positive as detected by an FDA-approved test in adults.	Formulary	02/01/2024
Ycanth (cantharidin)	treatment of molluscum contagiosum in adults and pediatric patients 2 years of age and older.	Non-Formulary	N/A
Zepbound (tirzepatide)	indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of ≥ 30 kg/m ² (obesity); or ≥ 27 kg/m ² (overweight) in the presence of at least one weight-related	Non-Formulary	N/A

January 2024 Pharmacy & Therapeutics Committee Decisions

	comorbid condition (e.g., hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease).		
Zurzuvae (zuranolone)	postpartum depression (PPD) in adults	Formulary	02/01/2024

Formulary changes for New Generics, New Indications and Miscellaneous Previously Reviewed drugs are effective 2/1/2024.

NEW INDICATIONS REVIEW		
DRUG	CURRENT FORMULARY STATUS	RECOMMENDATION
Lynparza (olaparib tablets)– Revised indication provides for restricting the indication for maintenance treatment of recurrent ovarian cancer to those patients with a germline breast cancer susceptibility gene (BRCA) mutation only	Formulary	Formulary
Yusimry (adalimumab-aqvh subcutaneous injection)– New indication for the treatment of non-infectious intermediate, posterior, and panuveitis in adults.	Non-Formulary	Non-Formulary
Temodar (temozolomide capsules)– New indication for the adjuvant treatment of newly diagnosed anaplastic astrocytoma in adults.	Non-Formulary	Non-Formulary
Jardiance (empagliflozin tablets) - New indication to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular (CV) death and hospitalization in adults with chronic	Formulary	Formulary

January 2024 Pharmacy & Therapeutics Committee Decisions

<p>kidney disease (CKD) at risk of progression.</p>		
<p>Bosulif (bosutinib tablets)– Expanded age indication to include patients 1 to < 18 years of age for chronic phase Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML).</p>	<p>Formulary</p>	<p>Formulary</p>
<p>Veltassa (patiromer oral suspension)– Expanded age indication to include patients 12 to < 18 years of age. Veltassa is now indicated for the treatment of hyperkalemia in adults and pediatric patients ≥ 12 years of age. Previously, Veltassa was only indicated in adults.</p>	<p>Formulary</p>	<p>Formulary</p>
<p>Zoryve (roflumilast cream, 0.3%)– Expanded age indication to include patients 6 years to < 12 years of age. Zoryve is now indicated for topical treatment of plaque psoriasis, including intertriginous areas, in patients ≥ 6 years of age.</p>	<p>Non-Formulary</p>	<p>Non-Formulary</p>
<p>Braftovi (encorafenib capsules) – New indication for use in combination with Mektovi® (binimetinib tablets), for the treatment of metastatic non-small cell lung cancer (NSCLC) in adults with BRAF V600E mutation, as detected by an FDA-approved test.</p>	<p>Formulary</p>	<p>Formulary</p>
<p>Mektovi (binimetinib tablets)– New indication for use in combination with Braftovi® (encorafenib capsules), for the treatment of metastatic non-small cell lung cancer (NSCLC) in adults with BRAF V600E mutation, as detected by an FDA-approved test.</p>	<p>Formulary</p>	<p>Formulary</p>

January 2024 Pharmacy & Therapeutics Committee Decisions

<p>Idacio (adalimumab-aacf injection)- New indication for the treatment of moderate to severe hidradenitis suppurativa in adults.</p>	<p>Non-Formulary</p>	<p>Non-Formulary</p>
<p>Keytruda (pembrolizumab intravenous infusion) – New indication for the treatment of patients with resectable (tumors ≥ 4 cm or node positive) non-small cell lung cancer (NSCLC) in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery.</p>	<p>Non-Formulary</p>	<p>Non-Formulary</p>
<p>Opdivo (nivolumab intravenous infusion) – Expanded indication to include the adjuvant treatment of completely resected stage IIB or IIC melanoma in adult and pediatric patients ≥ 12 years of age.</p>	<p>Non-Formulary</p>	<p>Non-Formulary</p>
<p>Enbrel (etanercept subcutaneous injection)- New indication for the treatment of active juvenile psoriatic arthritis (PsA) in patients ≥ 2 years of age. Enbrel is now indicated for the treatment of active juvenile PsA in pediatric patients ≥ 2 years of age.</p>	<p>Formulary</p>	<p>Formulary</p>
<p>Voxzogo (vosoritide subcutaneous injection)- Expanded age indication to include children under the age of 5 years. Voxzogo is now indicated to increase linear growth in pediatric patients with achondroplasia with open epiphyses. Previously, Voxzogo was indicated for pediatric patients ≥ 5 years of age.</p>	<p>Non-Formulary</p>	<p>Non-Formulary</p>

January 2024 Pharmacy & Therapeutics Committee Decisions

<p>Rozlytrek (entrectinib capsules)– Expanded age indication to include children > 1 month to < 12 years of age with solid tumors.</p>	<p>Non-Formulary</p>	<p>Non-Formulary</p>
<p>Tibsovo (ivosidenib tablets) – New indication for the treatment of relapsed or refractory myelodysplastic syndromes (MDS) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.</p>	<p>Formulary</p>	<p>Formulary</p>
<p>Vabysmo (faricimab-svoa intravitreal injection)– New indication for the treatment of macular edema following retinal vein occlusion (RVO).</p>	<p>Non-Formulary</p>	<p>Non-Formulary</p>
<p>Orencia (abatacept subcutaneous injection)– Expanded age indication to include patients 2 years to < 18 years of age with active psoriatic arthritis (PsA).</p>	<p>Formulary</p>	<p>Formulary</p>
<p>Cosentyx (secukinumab subcutaneous injection) - New indication for Cosentyx subcutaneous (SC) for the treatment of moderate to severe hidradenitis suppurativa (HS) in adults.</p>	<p>Non-Formulary</p>	<p>Non-Formulary</p>
<p>Voquezna (vonoprazan tablets) - New indication for healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults.</p> <p>New indication to maintain healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults.</p>	<p>Non-Formulary</p>	<p>Non-Formulary</p>

January 2024 Pharmacy & Therapeutics Committee Decisions

NEW GENERICS REVIEW		
DRUG	CURRENT FORMULARY STATUS	RECOMMENDATION
LITHIUM 8 MEQ/5 ML SOLUTION	Formulary	Non-Formulary
CLINDAMYC-BNZ PEROX 1.2-3.75% (ONEXTON)	Non-Formulary	Non-Formulary
KEMOPLAT 50 MG/50 ML VIAL	Non-Formulary	Non-Formulary
DEXTROAMPH-AMPHET ER 12.5 MG CAP DEXTROAMPH-AMPHET ER 25 MG CAP DEXTROAMPH-AMPHET ER 37.5 MG CAP DEXTROAMPH-AMPHET ER 50 MG CAP (MYDAYIS)	Non-Formulary	Non-Formulary
PAZOPANIB HCL 200 MG TABLET (VOTRIENT)	Non-Formulary	Formulary
COLCHICINE 0.6 MG CAPSULE (MITIGARE)	Non-Formulary	Non-Formulary
PITAVASTATIN 1 MG TABLET PITAVASTATIN 2 MG TABLET PITAVASTATIN 4 MG TABLET (LIVALO)	Non-Formulary	Non-Formulary
SPIRONOLACTONE 25 MG/5 ML SUSP (CAROSPIR)	Non-Formulary	Non-Formulary
LITHIUM 8 MEQ/5 ML SOLUTION	Formulary	Non-Formulary
CLINDAMYC-BNZ PEROX 1.2-3.75% (ONEXTON)	Non-Formulary	Non-Formulary

January 2024 Pharmacy & Therapeutics Committee Decisions

KEMOPLAT 50 MG/50 ML VIAL		
DEXTROAMPH-AMPHET ER 12.5 MG CAP DEXTROAMPH-AMPHET ER 25 MG CAP DEXTROAMPH-AMPHET ER 37.5 MG CAP DEXTROAMPH-AMPHET ER 50 MG CAP (MYDAYIS)	Non-Formulary	Non-Formulary
PAZOPANIB HCL 200 MG TABLET (VOTRIENT)	Non-Formulary	Formulary
COLCHICINE 0.6 MG CAPSULE (MITIGARE)	Non-Formulary	Non-Formulary

MISCELLANEOUS PREVIOUSLY REVIEWED ITEMS

DRUG	RATIONALE/ALTERNATIVE	RECOMMENDATION
EYLEA HD 8 MG/0.07 ML (AFLIBERCEPT) VIAL	Intravitreal injection	Non-Formulary
XDEMVIY 0.25% (LOTILANER) DROP	indicated to treat Demodex blepharitis, a chronic inflammation around the eyelashes, caused by infection with Demodex mites	Non-Formulary
AIRSUPRA 90-80 MCG (ALBUTEROL SULFATE/BUDESONIDE) INHALER	BUDESONIDE-FORMOTEROL, FLUTICASONE-SALMETEROL, ADVAIR HFA, AIRDUO, BREO ELLIPTA, DULERA, FLUTICASONE-VILANTEROL	Non-Formulary
IYUZEH 0.005% (LATANOPROST/PF) EYE DROP	BIMATOPROST, LATANOPROST, TAFLUPROST, TRAVOPROST	Non-Formulary
NITROFURANTOIN 50 MG/5 ML (NITROFURANTOIN)	NITROFURANTOIN capsules	Non-Formulary

January 2024 Pharmacy & Therapeutics Committee Decisions

SUSPENSION		
RYKINDO ER (RISPERIDONE MICROSPHERES)	ABILIFY ASIMTUFII, ABILIFY MAINTENA ER, INVEGA HAFYERA, INVEGA SUSTENNA, INVEGA TRINZA, RISPERDAL CONSTA	Non-Formulary
ILET INSULIN (SUBCUTANEOUS INSULIN PUMP) PUMP	OMNIPOD	Non-Formulary
TRIENTINE HCL 500 MG (TRIENTINE HCL) CAPSULE	TRIENTINE HCL 250 MG CAPSULE	Non-Formulary
GLIPIZIDE 2.5 MG (GLIPIZIDE) TABLET	GLIPIZIDE 5 MG TABLET	Non-Formulary
ADALIMUMAB-ADBIM	HUMIRA, HADLIMA	Non-Formulary
HYRIMOZ (ADALIMUMAB-ADAZ)	HUMIRA, HADLIMA	Non-Formulary
ABRILADA (ADALIMUMAB-AFZB)	HUMIRA, HADLIMA	Non-Formulary
POKONZA 10 MEQ (POTASSIUM CHLORIDE) PACKET	POTASSIUM CL	Non-Formulary
MOTPOLY XR (LACOSAMIDE) CAPSULE	LACOSAMIDE, VIMPAT	Non-Formulary
OJJAARA (MOMELOTINIB DIHYDROCHLORIDE) TABLET	JAKAFI	Non-Formulary
FLUTICASONE PROP (FLUTICASONE PROPIONATE)	FLOVENT, FLUTICASONE PROPIONATE HFA	Non-Formulary

January 2024 Pharmacy & Therapeutics Committee Decisions

DISKUS		
--------	--	--

ADDITIONAL ITEMS REVIEWED	
ITEM	DRUGS WITH NEW POLICIES
New Medical Drug Policies (effective 03/15/2024)	<ul style="list-style-type: none"> Adzynma Cosentyx IV Loqtorzi Omvoh Rivfloza Ryzneuta